22,666 Shares in Heron Therapeutics, Inc. (NASDAQ:HRTX) Acquired by Capstone Investment Advisors LLC

Capstone Investment Advisors LLC acquired a new stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) in the 3rd quarter, Holdings Channel reports. The firm acquired 22,666 shares of the biotechnology company’s stock, valued at approximately $45,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of HRTX. Capital Investment Counsel Inc increased its position in shares of Heron Therapeutics by 27.2% in the second quarter. Capital Investment Counsel Inc now owns 14,625 shares of the biotechnology company’s stock valued at $51,000 after buying an additional 3,125 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Heron Therapeutics by 15.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 29,922 shares of the biotechnology company’s stock valued at $83,000 after acquiring an additional 3,991 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in Heron Therapeutics by 16.0% during the second quarter. The Manufacturers Life Insurance Company now owns 45,771 shares of the biotechnology company’s stock worth $160,000 after acquiring an additional 6,328 shares during the last quarter. nVerses Capital LLC purchased a new stake in shares of Heron Therapeutics in the second quarter valued at about $27,000. Finally, Wealth Enhancement Advisory Services LLC grew its position in shares of Heron Therapeutics by 21.2% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 45,273 shares of the biotechnology company’s stock valued at $90,000 after purchasing an additional 7,927 shares during the last quarter. 80.01% of the stock is owned by institutional investors and hedge funds.

Heron Therapeutics Stock Performance

Shares of HRTX opened at $1.19 on Monday. The company has a market capitalization of $181.00 million, a price-to-earnings ratio of -6.61 and a beta of 1.81. Heron Therapeutics, Inc. has a 1 year low of $1.04 and a 1 year high of $3.93. The company’s 50 day simple moving average is $1.67 and its 200 day simple moving average is $2.40.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.03) EPS for the quarter, meeting analysts’ consensus estimates of ($0.03). The company had revenue of $32.81 million for the quarter, compared to analyst estimates of $36.40 million. During the same period in the prior year, the company earned ($0.17) EPS. Equities analysts expect that Heron Therapeutics, Inc. will post -0.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on HRTX. Needham & Company LLC cut their price objective on Heron Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. StockNews.com cut Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, November 21st.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.